EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Primary Cutaneous Melanoma—Management in 2024

Anthony Joseph Dixon iD, Michael Sladden, Christos C Zouboulis iD, Catalin M Popescu, Alexander Nirenberg iD, Howard K Steinman iD, Caterina Longo, Zoe Lee Dixon, Joseph Meirion Thomas

Journal of Clinical Medicine · 11.03.2024 · 13 (6) · 1607

DOI: 10.3390/jcm13061607 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 11.03.2024. Verfasst von Anthony Joseph Dixon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research, Australasian College of Cutaneous Oncology, Docklands, VIC 3008, Australia. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Maximizing survival for patients with primary cutaneous melanomas (melanomas) depends on an early diagnosis and appropriate management. Several new drugs have been shown to improve survival in high-risk melanoma patients. Despite well-documented guidelines, many patients do not receive optimal management, particularly when considering patient age. Objective: to provide an update on melanoma management from the time of the decision to biopsy a suspicious skin lesion.

Methods

We reviewed melanoma-management research published between 2018 and 2023 and identified where such findings impact and update the management of confirmed melanomas. Pubmed, Google Scholar, Ovid and Cochrane Library were used as search tools.

Results

We identified 81 publications since 2017 that have changed melanoma management; 11 in 2018, 12 in 2019, 10 in 2020, 12 in 2021, 17 in 2022 and 18 in 2023.

Discussion

Delayed or inaccurate diagnosis is more likely to occur when a partial shave or punch biopsy is used to obtain the histopathology. Wherever feasible, a local excision with a narrow margin should be the biopsy method of choice for a suspected melanoma. The Breslow thickness of the melanoma remains the single most important predictor of outcome, followed by patient age and then ulceration. The BAUSSS biomarker, (Breslow thickness, Age, Ulceration, Subtype, Sex and Site) provides a more accurate method of determining mortality risk than older currently employed approaches, including sentinel lymph node biopsy. Patients with metastatic melanomas and/or nodal disease should be considered for adjuvant drug therapy (ADT). Further, high-risk melanoma patients are increasingly considered for ADT, even without disease spread. Invasive melanomas less than 1 mm thick are usually managed with a radial excision margin of 10 mms of normal skin. If the thickness is 1 to 2 mm, select a radial margin of 10 to 20 mm. When the Breslow thickness is over 2 mm, a 20 mm clinical margin is usually undertaken. In situ melanomas are usually managed with a 5 to 10 mm margin or Mohs margin control surgery. Such wide excisions around a given melanoma is the only surgery that can be regarded as therapeutic and required. Patients who have had one melanoma are at increased risk of another melanoma. Ideal ongoing management includes regular lifelong skin checks. Total body photography should be considered if the patient has many naevi, especially when atypical/dysplastic naevi are identified. Targeted approaches to improve occupational or lifestyle exposure to ultraviolet light are important. Management also needs to include the consideration of vitamin D supplementary therapy.

Schlagwörter

Stichwörter der Autor:innen

BAUSSSmanagementmelanomatreatment

Autor:innen und Institutionen

  • Department of Research, Australasian College of Cutaneous Oncology, Docklands, VIC 3008, Australia.
  • Research, American Osteopathic College of Dermatology, Kirksville, MO 63501, USA.
  • Department of Dermatology, University of Tasmania, Launceston, TAS 7005, Australia.
  • Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, 06847 Dessau, Germany.
  • Department of Dermatology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Department of Surgery, Campbell University, Buies Creek, NC 27506, USA.

ORCID-Profile: Anthony Joseph Dixon, Christos C Zouboulis, Alexander Nirenberg, Howard K Steinman

Zitieren

APA

Dixon, A. J., Sladden, M., Zouboulis, C. C., Popescu, C. M., Nirenberg, A., Steinman, H. K., Longo, C., Dixon, Z. L., & Thomas, J. M. (2024). Primary Cutaneous Melanoma—Management in 2024. Journal of Clinical Medicine, 13(6), 1607. https://doi.org/10.3390/jcm13061607

Vancouver

Dixon AJ, Sladden M, Zouboulis CC, Popescu CM, Nirenberg A, Steinman HK, et al. Primary Cutaneous Melanoma—Management in 2024. Journal of Clinical Medicine. 2024;13(6):1607. doi:10.3390/jcm13061607

BibTeX
@article{Dixon2024,
  author = {Dixon, Anthony Joseph and Sladden, Michael and Zouboulis, Christos C and Popescu, Catalin M and Nirenberg, Alexander and Steinman, Howard K and Longo, Caterina and Dixon, Zoe Lee and Thomas, Joseph Meirion},
  title = {Primary Cutaneous Melanoma—Management in 2024},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {6},
  pages = {1607},
  doi = {10.3390/jcm13061607}
}
Kostenlos starten →